Cary Street Partners’s Novo Nordisk NVO Stock Holding History

Cary Street Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316K	Sell	6,599 -862	-12%	-$37K	0.01%	792
2026 Q1	$274K	Sell	7,461 -767	-9%	-$36.3K	0.01%	738
2025 Q4	$419K	Buy	8,228 +3,588	+77%	+$183K	0.01%	641
2025 Q3	$257K	Sell	4,640 -17,936	-79%	-$1.05M	0.01%	721
2025 Q2	$1.56M	Sell	22,576 -8,003	-26%	-$544K	0.04%	347
2025 Q1	$2.12M	Buy	30,579 +2,527	+9%	+$209K	0.07%	278
2024 Q4	$2.41M	Buy	+28,052	New	+$3.03M	0.08%	244

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Cary Street Partners's NVO Position: Q2 2026 in Review

Cary Street Partners reduced its Novo Nordisk (NVO) stake by 12% in Q2 2026, selling an estimated $37K and leaving 6,599 shares worth $316K. The position accounts for 0.01% of the portfolio, ranked #792.

Cary Street Partners first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.41M in Q4 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Cary Street Partners held 6,599 shares of Novo Nordisk worth $316K as of Q2 2026.
Cary Street Partners sold 862 Novo Nordisk shares in Q2 2026, an estimated $37K.
Novo Nordisk made up 0.01% of Cary Street Partners's portfolio in Q2 2026, its #792 holding.
Cary Street Partners first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
Cary Street Partners's Novo Nordisk position peaked at $2.41M in Q4 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.